ArticleLeukemia2010
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.
Article in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.Haematologica · 2015Trial
- Comutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish.Blood advances · 2026Article
- Review
- Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation.Stem cell reviews and reports · 2024Article
- Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis.Caspian journal of internal medicine · 2024Review
- Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article.Global medical genetics · 2023Review
- Epigenetic regulation by ASXL1 in myeloid malignancies.International journal of hematology · 2023Review
- Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer.Cancer research · 2023Article
- Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia.Cancer cell international · 2021Article
- Identification of Common Driver Gene Modules and Associations between Cancers through Integrated Network Analysis.Global challenges (Hoboken, NJ) · 2021Article
- Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion.Head and neck pathology · 2021Article
- Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.American journal of hematology · 2021Article
- Murine Models of Myelofibrosis.Cancers · 2020Review
- A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.Journal of molecular medicine (Berlin, Germany) · 2020Review
- Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.Journal of clinical medicine · 2020Review
- RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.Journal of hematology & oncology · 2019Article
- The role of ASXL1 in hematopoiesis and myeloid malignancies.Cellular and molecular life sciences : CMLS · 2019Review
- Prediction of Driver Modules via Balancing Exclusive Coverages of Mutations in Cancer Samples.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.International journal of oncology · 2018Article
- Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.Blood · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
19865112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.